2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-176987
    TG (18:0_18:1_20:4) 91539-56-9
    TG (18:0_18:1_20:4) is a monoarachidonic triglyceride, belonging to the triacylglycerol lipid class.
    TG (18:0_18:1_20:4)
  • HY-176988
    TG (18:0_20:1_20:4)
    TG (18:0_20:1_20:4) is a monoarachidonic triglyceride, belonging to the triacylglycerol lipid class.
    TG (18:0_20:1_20:4)
  • HY-176989
    TG (16:0_16:0_20:4) 944336-76-9
    TG (16:0_16:0_20:4) is a monoarachidic acid triglyceride, belonging to the triacylglycerol lipid class.
    TG (16:0_16:0_20:4)
  • HY-176995
    AZ-GHS-38 1143021-16-2
    AZ-GHS-38 (compound 38) is an orally active CNS-penetrant inverse agonist of growth hormone secretagogue receptor (GHS-R1a) with an IC50 of 6.7 nM. AZ-GHS-38 results in acute reduction of food intake in wild-type mice. AZ-GHS-38 can be used for anti-obesity research.
    AZ-GHS-38
  • HY-177003
    SM (d18:1/15:0) 121999-58-4
    SM (d18:1/15:0) is a sphingomyelinase inhibitor. SM (d18:1/15:0) is promising for research of neurodegenerative diseases (e.g., Alzheimer's) and metabolic syndrome.
    SM (d18:1/15:0)
  • HY-177050
    RG-239 1199222-56-4 98%
    RG-239 is an orally active TGR5 agonist with an EC50 of 120 nM, significantly outperforming Betulinic acid (HY-10529) (EC50 = 1.04 μM). RG-239 demonstrates higher selectivity for TGR5 compared to the FXRα. RG-239 increases mitochondrial activity in adipocytes and promotes neurite outgrowth at higher concentrations. RG-239 inhibits LPS (HY-D1056)-induced iNOS expression and nitrite production in Raw264.7 and microglia cells. RG-239 can be used for the study of type 2 diabetes[1][2][3][4][5].
    RG-239
  • HY-177136
    ACLY-IN-2 3009136-86-8
    ACLY-IN-2 (Compound 7) has inhibitory effect against human ATP citrate lyase (hACLY), with an IC50 of less than 1 nM. ACLY-IN-2 can be studied in research on liver-related diseases, type-2 diabetes, autoimmunity, and cancer.
    ACLY-IN-2
  • HY-177156
    Glucagon receptor antagonist-8 208182-31-4
    Glucagon receptor antagonist-8 (Compound 1) is a human glucagon receptor and p38 mitogen-activated protein (MAP) kinase antagonist, with IC50s of 0.27 μM and 0.16 μM, respectively.
    Glucagon receptor antagonist-8
  • HY-177296
    GPR40 agonist 8 1905451-62-8
    GPR40 agonist 8 (Compound 2) is a GPR40 agonist with an EC50 of 5 nM for hGPR40 Ca2+. GPR40 agonist 8 can be used in the research of diseases such as Type II diabetes and obesity.
    GPR40 agonist 8
  • HY-177297
    LCZ960 1067877-83-1
    LCZ960 is an orally active glucokinase (GK) activator. LCZ960 stimulates GK activity in hepatocytes in vitro and stimulates glucose uptake in vivo through hepatic GK activation. LCZ960 lowers blood glucose in mice with diet-induced obesity (DIO). LCZ960 maintains normoglycemia and improves glucose tolerance in DIO mice and rats. LCZ960 stimulates glycogen synthase flux and increases hepatic glycogen turnover in rats. LCZ960 induces increased hepatic glycogen recycling. LCZ960 can be used to study high-fat diet-induced obesity and type 2 diabetes.
    LCZ960
  • HY-177303
    AXT-914 717104-43-3 98.83%
    AXT-914 is a Calcium-sensing receptor (CaSR) inhibitor. AXT-914 has antiviral activity against the coronavirus HCoV 229E and SARS-CoV2. AXT914 reduces cytosolic calcium signalling activity of CaSR mutations. AXT-914 can be used for Bartter syndrome type 5 and autosomal dominant hypocalcemia (ADH) and coronavirus infections research.
    AXT-914
  • HY-177311
    NVP-QBE170 1080018-61-6
    NVP-QBE170 is a selective Epithelial sodium channel (ENaC) inhibitor with an IC50 of 57.5 nM. NVP-QBE170 potently inhibits ENaC function in HBECs and shows a longer duration of action. NVP-QBE170 significantly attenuates ENaC activity in the airways of guinea pig models. NVP-QBE170 can be used for hyperkalaemia research.
    NVP-QBE170
  • HY-177425
    AM11542 152674-95-8 98%
    AM11542 is a cannabinoid receptor 1 (CB1) agonist with a human CB1 Ki of 0.11 nM. AM11542 stabilizes the active conformational state of the CB1 receptor. AM11542 can be used for the research of obesity.
    AM11542
  • HY-177433
    NEK7 degrader-4 3069891-88-6 98%
    NEK7 degrader-4 is a NEK7 molecular glue degrader with a DC50 of 9  nM. NEK7 degrader-4 can be used for autoinflammatory and autoimmune disorders like multiple sclerosis, neurodegeneraive diseases like Alzheimer's disease and cardiovascular and melabolic disorders like pericarditis and Type 2 diabetes research.
    NEK7 degrader-4
  • HY-177506
    FE100726 158459-39-3
    FE100726 (Compound 39) is a Cholecystokinin 2 (CCK2) receptor agonist. FE100726 has a superior binding capacity on CCK2 receptor. FE100726 can induce gastric acid secretion in anaesthetized rat models. FE100726 can be used for diabetes research.
    FE100726
  • HY-177507
    FE101120
    FE101120 is a non-peptide agonist CCK2 receptor agonist. FE101120 can be used for the study of diabetes.
    FE101120
  • HY-177509
    BBL454
    BBL454 (Compound 43) is a Cholecystokinin 2B (CCK2B) receptor agonist. BBL454 induces hyperactivity and improves memory in rat models while it has weak activity on the peripheral CCK2 receptor and no anxiogenic activity. BBL454 increases gastric acid output in anesthetised rat models. BBL454 can be used for diabetes research.
    BBL454
  • HY-177534
    MGL-IN-2 1252773-92-4 98%
    MGL-IN-2 (Compound 1) is a MGL inhibitor with IC50 values of 0.006 μM and 0.0121 μM for mutant MGL and wild-type MGL, respectively. MGL-IN-2 can be used in the research of metabolic diseases.
    MGL-IN-2
  • HY-177622
    Cibrigirsen 160614-28-8
    Cibrigirsen is an antisense oligonucleotide targeted to the insulin-like growth factor I receptor(IGF-1R).
    Cibrigirsen
  • HY-177634
    Gatuzosiran 2409783-34-0 98%
    Gatuzosiran, a siRNA,is a 17-beta-hydroxysteroid dehydrogenase 13 (HSD17B13) synthesis reducer. It is used for the study of fatty liver disease.
    Gatuzosiran
Cat. No. Product Name / Synonyms Application Reactivity